A Randomized Prospective, Multicentric, Open Label, Phase II Study Aiming to Evaluate the Efficacity and Safety of EVEROLIMUS as Neo-adjuvant Therapy in Patients With Primary or Relapsed Chondrosarcomas

Trial Profile

A Randomized Prospective, Multicentric, Open Label, Phase II Study Aiming to Evaluate the Efficacity and Safety of EVEROLIMUS as Neo-adjuvant Therapy in Patients With Primary or Relapsed Chondrosarcomas

Suspended
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Chondrosarcoma
  • Focus Biomarker; Therapeutic Use
  • Acronyms CHONRAD
  • Most Recent Events

    • 21 Nov 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2018.
    • 21 Nov 2016 Status changed from recruiting to suspended since July 27th 2016 because of unavailability of Everolimus.
    • 10 Feb 2015 Status changed from not yet recruiting to recruiting according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top